An interim final rule that would require pricing drugs on the U.S. market based on their prices in certain countries is set to take effect on Jan. 1, 2021. Industry experts claim it will have little effect on bringing down prices for consumers. Precision's Ryan Cox joins other experts in discussing the far ranging impact of the new rule.
The trend of using real-world evidence (RWE) in the healthcare industry continues to grow. But perhaps it has never been more important than it is now during the current pandemic. Precisions Dan Danielson and others discuss the benefits to be gained from using RWE in the search for potential diagnostics, drugs and vaccines for COVID-19.
Many highly specialized, expensive drugs are in protected categories that must be covered. With few other options, payers are digging in with more prior authorization and other utilization management tactics. Precision's Dominic Galante weighs in on the increasingly difficult path to securing prior payer approval for high cost drugs.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
